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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYCell therapies treating pathological muscle atrophy or damage requires an adequate quantity of muscle progenitor cells (MPCs) not
currently attainable from adult donors. Here, we generate cultures of approximately 90% skeletal myogenic cells by treating human em-
bryonic stem cells (ESCs)with theGSK3 inhibitorCHIR99021 followed by FGF2 andN2 supplements. Gene expression analysis identified
progressive expression of mesoderm, somite, dermomyotome, and myotome markers, following patterns of embryonic myogenesis.
CHIR99021 enhanced transcript levels of the pan-mesoderm gene T and paraxial-mesoderm genes MSGN1 and TBX6; immunofluores-
cence confirmed that 91% ± 6% of cells expressed T immediately following treatment. By 7 weeks, 47% ± 3% of cells were MYH+ve
myocytes/myotubes surrounded by a 43% ± 4% population of PAX7+ve MPCs, indicating 90% of cells had achieved myogenic identity
without any cell sorting. Treatment of mouse ESCs with these factors resulted in similar enhancements of myogenesis. These studies
establish a foundation for serum-free and chemically defined monolayer skeletal myogenesis of ESCs.INTRODUCTION
Cell therapies to reverse muscle atrophy and to strengthen
skeletal muscle would greatly enhance and extend the lives
of patients with muscle wasting conditions due to diseases
and/or aging. Embryonic stem cells (ESCs) have unlimited
proliferation potential, and no need for locating a suitable
immunotype-matched donor as with adult-derived stem
cells (Araki et al., 2013). However, a major obstacle in the
development of ESC-based therapies targeting muscle has
been the generation of a homogeneous myogenic popula-
tion from in vitro differentiation, thus requiring optimiza-
tion to enrich for muscle lineage cells.
Several studies have validated the potential ofmouse and
human ESCs (mESCs and hESCs, respectively) and induced
pluripotent stem cells (iPSCs), in skeletal muscle therapy
(Barberi et al., 2007; Chang et al., 2009; Darabi et al.,
2008, 2011a, 2011b, 2012; Sakurai et al., 2008). Cells
were differentiated into paraxial mesoderm-like muscle
progenitors, either by a standard serum-based embryoid
body (EB) differentiation protocol (Chang et al., 2009; Sa-
kurai et al., 2008) or by transient expression of PAX3 or
PAX7 (Darabi et al., 2008, 2011a, 2012). These in vitro
derived progenitors were able to engraft into adult myofib-
ers of mice, replenish the muscle stem cell (satellite cell)
niche, and enhance muscle contractile function (Chang
et al., 2009; Darabi et al., 2008, 2011a, 2012; Sakurai
et al., 2008). Despite promising results, these protocols
are not appropriate for the generation ofmuscle progenitor516 Stem Cell Reports j Vol. 3 j 516–529 j September 9, 2014 j ª2014 The Acells (MPC) for clinical applications due to the inefficiency
of differentiation and the use of viral vectors and potential
insertional mutations (Thomas et al., 2003).
Previous studies from our lab have used a serum-contain-
ing EB-induced differentiation supplemented with low
levels of retinoic acid (RA) to enhance myogenesis from
mouse (Kennedy et al., 2009) and human (Ryan et al.,
2012) ESCs. However, serum-containing EB-differentiation
of hESCs produced relatively low yields of skeletal muscle
(<5%) and is undefined (Al Madhoun et al., 2011; Kennedy
et al., 2009; Ryan et al., 2012). In contrast, directed differ-
entiation uses knowledge of embryogenesis to recreate
embryonic conditions in vitro using combinations of
signaling molecules, to support the differentiation into
one lineage (Murry and Keller, 2008). Applying the
serum-free directed differentiation approach should greatly
improve the efficiency of hESC-derived myogenesis for
molecular analysis and for future use in cell therapies.
Wnt signaling is critically important for the develop-
ment of the primitive streak and paraxial mesoderm (Liu
et al., 1999), marked by the T and MSGN1 or TBX6 genes,
respectively, and in the formation of posterior somites
and the tail bud (Takada et al., 1994), marked by the tran-
scription factors PAX3, MEOX1, and PAX7. In the canoni-
cal pathway (reviewed in Clevers, 2006), Wnt binds to
Frizzled cell-surface receptors, initiating a signaling cascade
that inhibits GSK3B, preventing B-CATENNIN (CTNNB1)
degradation, and allowing CTNNB1 to accumulate and
translocate into the nucleus. Nuclear CTNNB1 enhancesuthors
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cyte enhancer factors (Clevers, 2006).
It has previously been shown that the GSK3 inhibitor
CHIR99021 (CHIR) can augment mesoderm induction
(Tan et al., 2013), leading to cardiomyogenesis in ESCs
(Lian et al., 2012). Recombinant proteins BMP4 and ACTI-
VIN-A (INHBA) have similarly been used to induce meso-
derm and cardiac muscle from ESCs (Kattman et al.,
2011; Murry and Keller, 2008). These studies implicate
BMP4/INHBA or CHIR treatment as a potential method
for generating skeletal muscle. Furthermore, we have
shown that overexpression of WNT3A or CTNNB1 en-
hances the formation of premyogenic mesoderm in P19
embryonal carcinoma cells, resulting in increasedmyogen-
esis (Petropoulos and Skerjanc, 2002). The loss of CTNNB1
function via dominant-negative mutation or knockdown
results in the loss of MPC formation and myogenesis, sup-
porting the use of CHIR to induce myogenesis.
The PAX3/7 population that is present in the central
dermomyotome appears to represent an MPC pool that is
maintained throughout embryogenesis and is responsible
for almost all skeletal muscle (Buckingham, 2007; Kuang
et al., 2007). FGF2 prevents expression of the myoblast
commitment transcription factors MYF5, MYOD1, and
MYOG—collectively known as the myogenic regulatory
factors (MRF)—during satellite cell activation and thus
can be utilized to enhance proliferation of PAX3/7 express-
ing MPCs in vitro (Fedorov et al., 1998; Hall et al., 2010).
Satellite cells are more efficient in reconstituting the satel-
lite cell niche during transplantation into muscle if they
do not yet upregulate the MRFs (Kuang et al., 2007; Mon-
tarras et al., 2005). We have previously shown that N2 sup-
plementedmedia can enhance the terminal differentiation
of myoblasts and myocytes, which would ensure MPCs are
capable of complete myogenesis in vitro (Al Madhoun
et al., 2011; Ryan et al., 2012).
In this report, we describe the robust skeletal myogenesis
of hESCs and mESCs using CHIR to induce mesoderm,
FGF2 treatment to expand the MPC population, and
N2-mediated terminal differentiation. This chemically
defined, serum- and transgenic-free protocol yields a nearly
homogeneous myogenic population from hESCs, consist-
ing of 43% ± 4% PAX7+ve MPCs and 47% ± 3% Myosin
Heavy Chain+ve (MYH) skeletal muscle.RESULTS
GSK3 Inhibition Enhanced Premyogenic Mesoderm
Formation from Human ESC
Ourobjectivewas todevise a robust, serum-free directeddif-
ferentiation method to obtain skeletal muscle from hESC
in vitro. We adapted a recently developed chemicallyStem Celldefined, feeder-free culture system to both expand pluripo-
tent cells and inducemesodermdifferentiation (Chen et al.,
2011). E8 maintenance media and Matrigel extracellular
matrix were observed to support pluripotency based on
OCT4 expression, and hESCs retained a normal karyotype
after prolonged collagenase passaging (data not shown).
Removal of FGF2 and TGFB1 from E8 media—referred to
as E6 media—was observed to support cell expansion, but
not pluripotency based on the loss of OCT4, SOX2, and
NANOG gene and protein expression. Therefore, E6 me-
dium provided a basal medium to which myogenic-induc-
tive signalingmolecules could be added. To control seeding
density during differentiation procedures, hESCs were
seeded as single cells in E8 media supplemented with
ROCK inhibitor (Y27632) (Gauthaman et al., 2010). After
overnight seeding, E8 media and ROCK inhibitor were
removed and replacedwithmesendoderm inductive condi-
tions (R.L.C., S-P.D., and W.L.S., unpublished data).
Because previous studieshave shown thatCHIRor BMP4/
INHBA treatment enhancedmesoderm induction in hESCs
(Cao et al., 2013; Kattman et al., 2011; Lian et al., 2012), we
initially sought to determine an optimal dose of CHIR and/
or BMP4/INHBA to induce premyogenic mesoderm. For
optimization of CHIR treatment, concentrations of 2.5
and 10 mMwere chosen to encompass a range of concentra-
tions previously used to induce cardiac tissue-fated meso-
derm (Cao et al., 2013; Lian et al., 2012). Cells were plated
on matrigel-coated dishes overnight in the presence of
Y-27632 before differentiation was induced (Gauthaman
et al., 2010). Factors maintaining pluripotency were
removed from the media and treated with CHIR or vehicle
for 2, 4, and 8 days in length: time points that encompass
expression of T and early somite markers PAX3 and
MEOX1 in serum-EB induced skeletal myogenesis (Ryan
et al., 2012). Analysis by quantitative PCR (qPCR) showed
significant upregulation of T and MSGN1 after 2 days of
treatment with 10 mMCHIR, leading to significant upregu-
lation of PAX3 on day 8 (Figure 1A). Although 2.5 mMCHIR
treatment was able to upregulate T andMSGN1 expression
after 2 days of treatment, it did not upregulate PAX3 at
day 8 for any treatment length. Longer application of
10 mMCHIR, for 4 or 8 days, did not enhance PAX3 expres-
sion as effectively and appeared to have toxicity toward the
cells (data not shown). MEOX1 gene expression appeared
similar betweenbothCHIR concentrations. Thus, the appli-
cation of 10 mM CHIR for the first 2 days of differentiation
was determined optimal for enhancing the formation of
PAX3+ve premyogenic mesoderm.
We titrated levels of BMP4/INHBA to optimize T expres-
sion and found by qPCR that 40 ng/ml of BMP4/INHBA
enhanced T transcript levels, although not as efficiently
as CHIR treatment (Figure 1B). Furthermore, BMP4/
INHBA treatment did not significantly enhance MSGN1Reports j Vol. 3 j 516–529 j September 9, 2014 j ª2014 The Authors 517
Figure 1. Ten Micromolar CHIR Applied for 2 Days Produces Optimal Levels of Paraxial and Premyogenic Mesoderm Gene Expression
(A) hESCs were treated in monolayer with or without 2.5 or 10 mM CHIR for 2, 4, or 8 days. RNA was harvested at days 0, 2, and 8 to be
analyzed by qPCR for markers of early and premyogenic mesoderm. Results are expressed as fold change over day 0 (n = 3 independent
experiments, *p% 0.05 versus day 0, **p% 0.05 versus day 0 and control, ***p% 0.05 2.5 versus 10 mM).
(B) CHIR-differentiated cells were compared to BMP4/INHBA treatment by qPCR for markers of early mesoderm. (n = 3 independent
experiments, *p% 0.05 versus day 0, **p% 0.05 versus day 0 and control, ***p% 0.05 BMP4/INHBA versus CHIR).
(C) Schematic overview of the CHIR directed differentiation of hESCs on a nonlinear scale timeline, along with highlighting key sup-
plemental factors applied during the differentiation, and the predicted developmental stages of skeletal myogenesis.
(D) Representative phase contrast live-cell images demonstrating the progressive changes in hESC morphology with and without CHIR
treatment. 3D cell clusters (white arrowheads) and the presence of skeletal myocytes (black arrowheads) are indicated at specific time
points (scale bar, 20 mm).
Results are shown ±SEM.
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derm. Thus, CHIR treatment was better than BMP4/INHBA
treatment to induce premyogenic mesoderm in hESCs.
CHIR Treatment Resulted in up to 90% of hESCs
Entering the Myogenic Lineage
hESCs were differentiated using the 2 day CHIR treatment
protocol devised in Figure 1A and cultured until day 50 as518 Stem Cell Reports j Vol. 3 j 516–529 j September 9, 2014 j ª2014 The Asummarized in Figure 1C, outlining the stages of myo-
genesis and the chief chemical and recombinant factor
additions. Live-cell imaging was performed, showing the
progressive morphological changes from stem cells to
myotubes (Figure 1D). CHIR-treated cells appeared
morphologically distinct from control cells by day 2 of
differentiation, and proliferation was reduced as judged
by lower confluency compared to controls.uthors
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clusters (Figure 1D, white arrowheads) (Rohwedel et al.,
1994). FGF2 was applied from days 12 to 20, which corre-
sponds to the time frame that we previously detected so-
mite or MPC markers PAX3, MEOX1, and PAX7 along
with MYF5 (Ryan et al., 2012). Therefore, this time frame
was an ideal target for FGF2 treatment to preferentially
expandMPCs while suppressing early potential expression
of the MRFs. N2 supplemented media was applied at day
35—coinciding with later detection of all MRFs previously
(Ryan et al., 2012)—to promote maturation of the
myogenic cultures. Skeletal myocytes were observed by
day 40, following 5 days of culture in N2 medium (Fig-
ure 1D, black arrowheads). The myocytes were, for the
most part, randomly arranged among other nonbipolar
cells. By day 50, cultures revealed large areas of aligned
myocytes and fused myotubes, organized radially outward
from the 3D clusters (Figure S1 available online). No appre-
ciable skeletal myogenesis was observed in control cultures
that were given DMSO vehicle in place of CHIR from days
0 to 2 and treated identically to CHIR-treated cells there-
after. Thus, CHIR treatment resulted in the formation
of abundant mesoderm that could be developed into
easily visualized myocytes and myotubes by day 50 of
differentiation.
CHIR treatment resulted in detection of T protein in an
average of 91% ± 6% of cells on day 2, compared to no T
present in the control-treated cells (Figures 2A and 2E). At
day 8, an average of 58% ± 10% of cells expressed PAX3
after CHIR treatment compared to 1% ± 1% in control cells
(Figures 2B and 2F). Skeletal myocytes were prominent by
day 40 following 5 days of growth in N2 medium, with
an average of 14% ± 3% of CHIR-treated hESCs expressing
MYH and were surrounded by a 37% ± 2% population of
PAX7+ve cells (Figures 2C and 2G). In addition tomyocytes,
some myotubes were present (Figure S2A, white arrow-
heads), and skeletal muscle contractions could be observed
by light microscopy (Movie S1). When the cultures were
left inN2media fromday 35 until day 50, 43% ± 4%of cells
remained PAX7 positive, whereas 47% ± 3% were MYH
positive (Figures 2D and 2G). A macroscopic view of the
culture dishes suggests that the 3D clusters function as
myogenic foci, with high concentrations of PAX7+ve cells
delaminating from their edges and myocytes/myotubes
emanating outward (Figures S2B and S2C). Thus, CHIR/
FGF2/N2 treatment can induce around 90% of hESCs to
enter the myogenic lineage.
We also quantified total cell number at various time
points to investigate the scalability of hESC-derived my-
ogenic cells with our protocol. The total cell number fol-
lowed a logarithmic growth curve over the course of the
differentiation protocol, resulting in roughly 20-fold
more cells at day 50 compared to the initial number presentStem Cellat day 0 (Figure 2H). We also characterized the prolifera-
tion potential of our MPCs at day 50 by ethynyl-deoxyuri-
dine (EdU) incorporation (Figures 2I and S2D). During a
4 hr labeling pulse, 42% ±10% of PAX7+ve MPCs in-
corporated EdU, demonstrating that our differentia-
tion protocol yields a persistent population of actively
proliferating MPCs at the final time point assayed in these
studies.
We examined the temporal pattern of expression of
myogenic factors by qPCR during CHIR-directed differenti-
ation of hESCs to confirm the immunofluorescence results.
Day 2 of CHIR-treated hESCs showed significant upregula-
tion of T transcripts, that was orders of magnitude higher
than our previous results using a serum/EB method (Fig-
ure 3A) (Ryan et al., 2012). Significant upregulation of the
paraxial mesoderm markers MSGN1 and TBX6 accompa-
niedTat day 2, and all were downregulated by day 8, which
marked peaks of the premyogenic mesoderm genes PAX3
and MEOX1 (Figure 3B), in agreement with our previously
published results (Ryan et al., 2012). Two control patient-
derived iPSC lines showed similar mesoderm gene eleva-
tion in response to our CHIR-based protocol (data not
shown).
Expression of PAX3 and MEOX1 was downregulated by
day 25, although significant levels were still detected until
day 50 (data not shown). Although PAX7, MYF5, MYOD1,
and MYOG transcripts were significantly upregulated by
day 25, their expression continued to increase until day
50 (Figure 3C). Expression of MYH3 transcripts also
increased at days 40 and 50, suggesting an enduring MPC
population coexisting with terminally differentiated skel-
etal myocytes/myotubes in agreement with our immuno-
fluorescence data (Figures 2D, 2G, 2I, and S2D). Control
cells showed no significant expression of MYF5, MYOD1,
orMYH3 transcripts. There was, however, very low but sta-
tistically significant upregulated expression of PAX7 and
MYOG mRNA in control cells. Overall, CHIR-treated cells
exhibited waves of expression of mesoderm, presomitic
mesoderm,muscle progenitor, myoblast, andmuscle struc-
tural genes.
Because Wnt signaling is important for the development
of a multitude of tissues and not simply premyogenic
mesoderm (Clevers, 2006), we screened our cultures for
markers of other lineages. Therefore, we assayed for other
cell types that may be present in the 9% Tve cells early
in differentiation, and later in the 10%of PAX7ve/MYHve
cells. CHIR treatment led to a significant drop in the plurip-
otency marker SOX2 (Figure 4A) by day 2, indicating an
efficient loss of pluripotency. SOX2 is also expressed in
ectoderm lineages pertaining to the neural tube and future
spinal cord (D’Amour and Gage, 2003; Wood and Episko-
pou, 1999). Thus, levels of these tissues in our day 8
CHIR cultures should be low for SOX2 expression.Reports j Vol. 3 j 516–529 j September 9, 2014 j ª2014 The Authors 519
Figure 2. CHIR Directed Differentiation of hESCs Induces up to a 90% Myogenic Population
(A–G) hESCs were differentiated as described in Figure 1. Myogenic induction was quantified by staining with antibodies against (A) and
(E) T at day 2, (B) and (F) PAX3 at day 8, (C) and (G) MYH and PAX7 at day 40, and (D) and (G) MYH and PAX7 at day 50. Target populations
are expressed as a percentage of total number of cells, which was quantified by Hoechst staining (n = 3 independent experiments,
*p% 0.05 versus control, **p% 0.05 day 40 versus day 50, scale bar, 20 mm).
(H) Total number of cells was obtained by trypsinizing and counting one well of a 12-well culture dish at various time points of the
differentiation protocol (n = 3 independent experiments).
(I) Day 50 CHIR-treated cells were pulsed with EdU for 4 hr and fixed and stained additionally with PAX7. EdU and PAX7 single or double-
positive cells were quantified and expressed as percentage of total number of cells (n = 3 independent experiments).
Results are shown ±SEM.
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Figure 3. qPCR Profiling of CHIR-Treated
hESCs Highlights a Clear Progression
through Specified Mesodermal Subtypes,
Muscle Progenitor Stages, and Committed
Myogenic Cultures
hESCs were differentiated as described in
Figure 1. RNA was harvested at days 0, 2, 8,
25, 40, and 50 to be analyzed by qPCR for
markers several of (A) early and paraxial
mesoderm, (B) premyogenic mesoderm, and
(C) committed or differentiated skeletal
muscle. Results are expressed as fold
change over day 0 (n = 3 independent
experiments, *p % 0.05 versus day 0, **p
% 0.05 versus control).
Results are shown ±SEM.
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Efficient Derivation of PAX7+ve MPCs from ESCsFOXA2—a marker of notochord, floor plate, and future
endoderm (Monaghan et al., 1993; Sasaki and Hogan,
1993)—was reduced in both CHIR-treated and control
cells. Significant upregulation of NOG and SOX10 was de-
tected at day 8 of CHIR-mediated differentiation, which
conventionally mark the roof plate and neural crest during
embryonic development (Pusch et al., 1998; Valenzuela
et al., 1995). Although neural crest cells may have been pre-
sent early in differentiation, there was no significant upre-
gulation in the neuronal marker NEUROG1 at later timeStem Cellpoints (Figure 4B), and immunofluorescent staining for
NEFL—a neurofilament protein expressed in central and
peripheral nervous system axons—was also negative (data
not shown). Significant expression of traditional cardiac
muscle lineage genesNKX2-5 andMYH6 (Akazawa and Ko-
muro, 2005; Lyons et al., 1990) was detected with CHIR
treatment at day 50, although cells exhibiting a cardiac
muscle phenotype were not readily observed in these
cultures (Figure S2B). As NKX2-5 and MYH6 have previ-
ously been detected in developing tongue skeletal muscleReports j Vol. 3 j 516–529 j September 9, 2014 j ª2014 The Authors 521
Figure 4. Low Levels of Neural Crest
Transcripts Were Present in CHIR-Treated
Cultures
hESCs were differentiated, harvested, and
analyzed as described above for markers of
(A) pluripotency and neural ectoderm
markers, (B) differentiated neural and
traditional cardiac markers, (C) specific
markers of mature cardiomyocytes, and (D)
patterned dermomyotome genes (n = 3 in-
dependent experiments, *p % 0.05 versus
day 0, **p % 0.05 versus control). In (C)
RNA from serum-differentiated hESCs and
human heart (HH) cardiomyocyte-positive
controls were obtained (n = 1). All hESC fold
changes (black bars) were plotted on the
primary y axis, and HH fold change (gray
bar) was plotted on the secondary y axis.
Results are shown ±SEM.
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markers that are expressed exclusively in cardiomyocytes,
NPPA and MYL2. No expression of these markers was de-
tected in our day 50 differentiated cultures (Figure 4C).
Therefore, neither mature neuronal tissue nor cardiac mus-
cle were present in terminally differentiated cultures.
To determine the patterning of the dermomyotome, we
performed qPCR for the regional dermomyotome markers
EN1, SIM1, LBX1, and MET (Figure 4D). The dermomyo-
tome is patterned into the dorsomedial half—expressing
EN1 and giving rise to epaxial muscle, forming the deep
back muscles—and the ventrolateral half, expressing
SIM1 and giving rise to hypaxial muscle, forming the
ventral and limb muscle (Cheng et al., 2004; Ordahl and522 Stem Cell Reports j Vol. 3 j 516–529 j September 9, 2014 j ª2014 The ALe Douarin, 1992; Pourquie´ et al., 1996). Proper migration
of the hypaxial MPCs into the limb requires the expression
of LBX1 andMET (Vasyutina and Birchmeier, 2006). There-
fore, presence of LBX1 andMET expression would support
the existence of MPCs similar to those found in migrating
limb muscle. We found a significant increase of the three
regional markers of the dermomyotome—EN1, SIM1,
LBX1—and a trend toward elevatedMETwith CHIR. How-
ever,MET was expressed at high levels throughout the dif-
ferentiation, shown by low Ct values, making changes as a
result of CHIR-treatment difficult to identify (data not
shown). Thus, day 25–50 cultures containing muscle pro-
genitors expressedmarkers of epaxial, hypaxial, andmigra-
tory dermomyotome.uthors
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Mouse ESCs
A similar CHIR-based differentiation protocol was per-
formed in mouse embryonic stem cells (mESCs) and
compared with BMP4/INHBA-mediated differentiation.
Pax3/7+ve cells, presumably representing MPCs, were pre-
sent in both BMP4/INHBA- and CHIR-treated mESCs at
day 15, although PAX3/7+ve cells were visibly more abun-
dant with CHIR (Figure 5A). Interestingly, MYH staining
primarily revealed cardiomyocytes in BMP4/INHBA-
treated cultures despite the presence of PAX3/7+ve cells (Fig-
ure 5B). CHIR, conversely, promoted the differentiation of
primarily skeletal and not cardiac myocytes. Control cul-
tures showed negligible or no staining with either PAX3/
7 or MYH antibodies. Thus, CHIR treatment upregulated
PAX3/7 expression, leading to enhanced skeletal myogen-
esis in mESCs.
Established markers of skeletal myogenesis were exam-
ined by qPCR and demonstrated corroborating trends
between CHIR-induced differentiation in mESCs and
hESCs (Figure 5C). Indeed, CHIR treatment significantly
enhanced the expression of key paraxial mesoderm,
premyogenic mesoderm, and MRF genes, including T,
Msgn1, Pax3, Meox1, Myod1, Myog, and Myh3.
BMP4/INHBA-treated cells exhibited some upregulation
of the same mesodermal genes. However, BMP4/INHBA
treatment did not upregulate expression of the MRFs but
did upregulate high levels of the cardiomyocyte markers
Nkx2-5 andMyh6. Thus,mESCs respond toCHIR treatment
by upregulating a similar set of muscle lineage genes as
identified in hESCs, albeit in a much-reduced time frame.DISCUSSION
Our studies define a method whereby human and mouse
ESCs are differentiated in vitro into highly enriched popu-
lations of skeletal muscle progenitor cells and myocytes/
myotubes by activating Wnt signaling via the GSK3 inhib-
itor CHIR99021. A mere 2 day exposure to the compound
causes immediate changes in growth and morphology to-
ward mesoderm, and sets in motion downstream cascades
of myogenic transcription factors across weeks of culture.
In due course, we achieve approximately 90% purity of
skeletal muscle lineage cells from hESCs after 50 days in
culture.
Although forced expression of PAX3/7 or MYOD in
hESCs have resulted in enrichedmyogenic populations (Al-
bini et al., 2013; Darabi et al., 2012; Goudenege et al., 2012;
Rao et al., 2012), we sought to develop a viral- and trans-
genic- free method of in vitro differentiation. A chemically
defined protocol should be more readily adaptable to a
broader number of cell lines and should allow for the exam-Stem Cellination of all of the stages of differentiation, some of which
may be bypassed by transgenic overexpression (Albini
et al., 2013).
Our study contrasts with previously published methods
of transgene-free hESC myogenesis that were dependent
upon serum, showing low overall myogenic induction
and/or myogenic progenitor formation (Awaya et al.,
2012; Hwang et al., 2013; Ryan et al., 2012). For example,
we previously obtained a 4% level of MYH+ve skeletal myo-
cytes and 7%PAX3+veMPCswith RA treatment (Ryan et al.,
2012). Our current CHIR-directed protocol improves on
the serum/EB methods by directing a larger proportion of
the cultures into mesoderm, leading to enriched myogenic
lineage populations.
Several studies have shown that Wnt signaling modula-
tion by CHIR can maintain ESC pluripotency (Wu et al.,
2013), and also can cause differentiation into tissues of all
three germ layers (Denhamet al., 2012; Lian et al., 2012; Ta-
hamtani et al., 2013). However, supporting factors were
required immediately following CHIR treatment for these
approaches. Cell seeding density may also determine how
GSK3 inhibition cangenerate skeletalmuscle specificmeso-
dermversus other cell fates. Seeding densitywas critical first
and foremost in determining how hESCs responded to
external differentiation cues in our system (R.L.C., S-P.D.,
and W.L.S., unpublished data). At lower seeding densities
(<1 3 105 cells/ml), hESC survival was reduced even in the
presence of ROCK inhibitor, suggesting that cell-cell con-
tacts are important for the initial seeding process. Addition-
ally, sparse populations of cells responded to BMP4/INHBA
treatment with increased cell death compared to higher
densities. Furthermore, at higher seeding densities (>2 3
105 cells/ml), overconfluence was observed after 48 hr,
again leading to compromised cell viability. Other mono-
layer approaches have used GSK3 to drive cardiomyogene-
sis; however, these protocols induce GSK3 inhibition once
cells reach confluence or with supplemental BMP4 inhibi-
tion (Cao et al., 2013; Lian et al., 2012). These protocols
also emphasize the critical importance of insulin depletion
after GSK3 inhibition, or the need for Wnt inhibition
following mesoderm induction lest cardiomyogenesis will
not occur in vitro (Kattman et al., 2011; Lian et al., 2013).
This is supported by the role of Dkk-mediated Wnt inhibi-
tion in specifying embryonic mesoderm to the primary
heart field (Ueno et al., 2007).
Of particular relevance to the results presented in our
study was the differentiation of mesoderm from hESCs
via 5 days of 5 mMCHIR treatment (Tan et al., 2013). Inter-
mediate to the desired cell types, CHIR treatment caused a
marked upregulation of TmRNA and protein levels, similar
to our findings. Though the authors followed CHIR treat-
ment with BMP4—which typically effects lateral plate
mesoderm—to develop hematopoietic and endothelialReports j Vol. 3 j 516–529 j September 9, 2014 j ª2014 The Authors 523
Figure 5. CHIR Enhances Skeletal Myogenesis in a 15 Day Differentiation of mESCs
mESCs were aggregated in differentiation medium for 2 days prior to treatment. CHIR, BMP4/INHBA, or vehicle control was applied from
days 2 to 4.
(A and B) Immunofluorescent staining was carried out at day 15 with antibodies against (A) PAX3 and PAX7 or (B) MYH (scale bar, 20 mm).
(C) RNA was harvested at days 0 and 2 (prior to CHIR treatment) and days 4, 6, and 15 (following treatment). Samples were analyzed by
qPCR for select markers of skeletal and cardiomyogenesis.
Results are expressed relative to the maximum fold change over day 0 (n = 3 independent experiments, *p% 0.05 versus day 0, **p% 0.05
versus day 0 and control, ***p% 0.05 BMP4/INHBA versus CHIR). Results are shown ±SEM.
524 Stem Cell Reports j Vol. 3 j 516–529 j September 9, 2014 j ª2014 The Authors
Stem Cell Reports
Efficient Derivation of PAX7+ve MPCs from ESCs
Stem Cell Reports
Efficient Derivation of PAX7+ve MPCs from ESCscell types and not skeletal muscle (Pick et al., 2007; Rufai-
hah et al., 2011). They also found INHBA following CHIR
treatment was necessary for pronounced endoderm
commitment (Tan et al., 2013).
AlthoughCHIR can coax differentiation of hESCs into all
three germ layers, we obtained surprisingly 43% ± 4%
PAX7+ve and 47% ± 3% MYH+ve cell populations at the
experimental endpoint. However, trace expression of other
ectoderm and mesoderm lineages can be detected early in
the protocol. It is possible that other tissues, such as neural
crest present early in our protocol, aid in the myogenic dif-
ferentiation pathway; attempts to reach 100% T+ve cultures
could demand additional signaling molecules to replace
factors from these tissues (Nitzan and Kalcheim, 2013;
Rios et al., 2011). It is likely that our current protocol can
still be improved by the inclusion of additional signaling
molecules at the correct time in the pathway, such as RA
andNotch signaling, and/or by the use of fluorescence-acti-
vated cell sorting (FACS) or microdissection to further
enrich the MPCs.
Indeed, we attempted to improve our protocol according
to a recent study published while ourmanuscript was in re-
view that generated high proportions of skeletal myocytes
from aggregated human iPSCs using combinatorial treat-
ment with CHIR, FGF2, and the cAMP signaling activator
Forskolin (Xu et al., 2013). Hence, we included Forskolin
in our culture system to determine whether activation of
cAMP signaling with could improve skeletal myocyte yield
in the context of our protocol (Figure S3). qPCR analysis
showed that, in the context of our monolayer differentia-
tion protocol with 10 mM CHIR alone, Forskolin does not
provide additional benefit to myogenesis as it does with
aggregate based differentiation. By day 7, however, condi-
tions that included Forskolin were observably denser
than CHIR alone treated cultures, suggesting that Forskolin
increases cell proliferation (data not shown). One major
difference between our protocol and the published work
by Zon and colleagues is that the myogenic cultures gener-
ated with Forskolin treatment appear to terminally differ-
entiate beyond the MPC stage to over 90% MYOG+ve (Xu
et al., 2013), whereas our system maintained a significant
population of proliferating PAX7+ve MPCs (Figures 2D,
2G, 2I, and S2D), suggesting that our culture system will
provide replicative MPCs that could maintain homeostasis
in the transplanted muscle.
During the revisions of this manuscript, two additional
manuscripts were published that generated transgene-free
human ESC myocytes. Barberi and colleagues utilized a
lower concentration of CHIR and longer treatment dura-
tion to direct skeletal myogenesis in embryonic stem cells
(Borchin et al., 2013). We initially determined that similar
CHIR conditions used by Borchin et al. (2013) induced less
skeletal muscle-specific mesoderm than the optimal 10 mMStem Cellfor 2 days (Figure 1A). Indeed, our protocol generated twice
as many PAX7+ve MPCs at comparable time points (Figures
2C and 2G). This recent publication, however, introduced
a rigorous HNK/ACHR/CXCR4+/MET+ FACS profile for
isolating MPCs from bulk cultures. Therefore, future
studies in embryonic-derived MPCs may benefit from im-
plementing our differentiation protocol to generate greater
numbers of starting cells, which could be enriched via the
HNK/ACHR/CXCR4+/MET+ profile.
In addition, Suzuki and colleagues present a viable alter-
native to monolayer directed skeletal myogenesis (Ho-
soyama et al., 2014). The authors’ ‘‘EZ Sphere’’ suspen-
sion-culture system uses high concentrations of FGF2 and
EFGF to yield remarkably similar proportions of PAX7+ve
populations at the experimental endpoint as those pre-
sented here (Figures 2D, 2G, 2I, and S2D). One caveat to
the EZ Sphere method, however, is potentially upward of
30% of cells are neural progenitors (Hosoyama et al., 2014).
We show that CHIR can mediate efficient skeletal myo-
genesis in mESCs using a 2 day CHIR treatment similar to
that used for hESCs, illustrating the effectiveness of our
protocol across these species. Our current findings are
consistent with our previous results showing that Wnt
signaling via CTNNB1 is important for murine P19 embry-
onal carcinoma cell differentiation, using gain- and loss-of-
function as well as a dominant-negative approach (Petro-
poulos and Skerjanc, 2002; Wong et al., 2013). In addition,
the greater experimental variability with mouse compared
to human ESC differentiation into muscle could be due to
the EB-based nature of the mESC serum-free protocol.
Therefore, we are adapting the more consistent monolayer
approach used with our hESCmethod to mESCs. Although
hESCs are more therapeutically relevant, mESCs continue
to play an integral role in our ability to study cellular differ-
entiation, primarily due to their substantially shorter dif-
ferentiation time, creating a simpler high-throughput
model system for detailed molecular analysis.
Overall, the results presented here have provided a
method to differentiate mouse and human ESCs into high-
ly enriched skeletal muscle lineage cultures. Most impor-
tantly, we show a stable PAX7+ve population of MPCs
even after 7 weeks of culture. Ultimately, these studies pro-
vide the foundation for in vitro study of ESC skeletal myo-
genesis, which could contribute to future drug testing or
stem cell therapies, leading to the repair of muscle in pa-
tients with muscular wasting disorders.EXPERIMENTAL PROCEDURES
Human Cell Culture
All hESC media and components are formulated in Table S1. H9
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Efficient Derivation of PAX7+ve MPCs from ESCs-coated dishes in E8 media prepared in lab (Chang et al., 2013;
Chen et al., 2011; Thomson et al., 1998).
Cells were prepared for differentiation by plating 1.5 3 105 cells
per well on BDMatrigel coated 12-well dishes in E8 supplemented
with 10 mM Y-27632 (Tocris Bioscience) overnight. The medium
was then replacedwith E6medium (Thomson et al., 1998), supple-
mented with CHIR99021 (Tocris Bioscience) or BMP4 and INHBA
(R&D Systems) for 2 days. DMSO was used as the vehicle control
at a final concentration of 0.1%. CHIR99021 or BMP4 and INHBA
werewashedout at day 2, and cells were grown in unsupplemented
E6 until day 12. From days 12 to 20, themediumwas replacedwith
StemPro-34media. Cells were returned to E6media fromdays 20 to
35. The medium was then replaced with N2 medium until the
endpoint of the experiment. All media were changed daily.
When indicated (Figure S3), 20 mM Forskolin (Tocris Bioscience)
and 10 ng/ml FGF2 was used from days 0 to 7 in conjunction
with 0.5 mM CHIR99021, or from days 2 to 7 following 2 days of
10 mM CHIR99021 treatment.Mouse Cell Culture
All mESC media and components are formulated in Table S2. R1
mESCs were maintained feeder free and passaged every other day
in Maintenance Media, prepared in lab.
Cells were prepared for differentiation by plating 5 3 105 cells
on 0.1% gelatin coated 10 cm dishes overnight in Serum Free
Maintenance Media to deplete serum (Kattman et al., 2011). The
cells were then trypsinized and aggregated into embryoid bodies
at 1 3 105 cells/ml on Petri dishes in Serum Free Differentiation
Medium for 2 days. At day 2, EBswere trypsinized and reaggregated
at 1 3 105 cells/ml on Petri dishes in Serum Free Differentiation
Media—supplemented with 5 ng/ml VEGF (R&D Systems), and
either CHIR99021 or BMP4/INHBA—from days 2 to 4 of differen-
tiation. DMSOwas used as the vehicle control at a final concentra-
tion of 0.1%. From days 4 to 10, the medium was replaced with
StemPro-34 Media. EBs were plated on BD Matrigel coated dishes
on day 6. The medium was replaced at day 10 with N2 medium
until the endpoint of the experiment. All media were changed
every other day.Gene Expression Analysis
RNA was isolated from cells using either the RNeasy kit (QIAGEN)
or Total RNAMini Kit (FroggaBio). RNA ranging from 0.2 to 1 mg of
each sample was reverse transcribed using the Quantitect Reverse
Transcription kit (QIAGEN). qPCR was carried out using a Master-
cycler Realplex and analyzed with Realplex software (Eppendorf).
For real-time detection of mRNA expression, 1/40 of the total first
strand synthesis product was used as a template for PCR amplifica-
tion using either GoTaq qPCRMaster Mix (Promega) or Kapa SYBR
Fast qPCR kit (Kapa Biosystems). Primer pairs (Table S3) were
selected from PrimerBank (Wang and Seed, 2003) or generated by
Primer-BLAST (Altschul et al., 1990) and tested for equivalent effi-
ciency. Each reactionwas carried out in duplicate, and fold changes
were calculated using the comparative Ct method as described
earlier (Livak and Schmittgen, 2001). The resulting Ct values
were normalized to either GAPDH in hESCs or Actb in mESCs. Re-
sults are shown ±SE of the mean of three independent experi-
ments, unless otherwise stated.526 Stem Cell Reports j Vol. 3 j 516–529 j September 9, 2014 j ª2014 The AImmunofluorescence
Cells were fixed for immunofluorescence with 4% formaldehyde
for 15 min and permeabilized with PBS containing 0.5% Triton
X-100 for 10 min. Cells were then blocked for 1 hr with PBS con-
taining 0.1% bovine serum albumin, 0.1% Triton X-100, and
10% goat or donkey serum. Primary antibodies against T (Abcam),
PAX3 (R&D Systems), PAX7 and MF20 (Developmental Studies
Hybridoma Bank), or NEFL (Sigma-Aldrich) were incubated over-
night at 4C. Cy3-conjugated donkey anti-rabbit, goat anti-mouse
IgG2a, goat anti-mouse IgG2b, Alexa-488-conjugated donkey anti-
goat, andDyLight488-conjugated goat anti-mouse IgG1 secondary
antibodies (Jackson ImmunoResearch) were used for detection as
appropriate for 1 hr at room temperature. Cells were mounted in
sPBS:glycerol containing Hoechst dye to identify cell nuclei. EdU
labeling was performed using the Click-iT EdU Alexa Fluor488 Im-
aging Kit (Life Technologies). Cells we pulsed with EdU for 4 hr
before fixing and staining as per the manufacturer’s protocol.
Cells were visualized with a Leica DMI6000 B microscope (Leica
Microsystems), and pictures were acquired using a Micropublisher
3.3 RTV camera (Q Imaging). Staining was quantified by perform-
ing either manual or automated cell counts using the Volocity
software (PerkinElmer) and represented as a proportion of total
nuclei. On average, 2.5 3 104 cells were quantified from each
experiment. Results are shown ±SE of the mean of three indepen-
dent experiments.Statistical Analysis
Statistical differences between means were calculated using the
Student’s t test. p values% 0.05 were considered significant.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures, three tables, and
one movie and can be found with this article online at http://dx.
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